Free Trial
NASDAQ:ATXS

Astria Therapeutics (ATXS) Stock Price, News & Analysis

Astria Therapeutics logo
$5.97 -0.27 (-4.33%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$5.96 -0.01 (-0.17%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Astria Therapeutics Stock (NASDAQ:ATXS)

Key Stats

Today's Range
$5.94
$6.31
50-Day Range
$3.90
$6.77
52-Week Range
$3.56
$12.92
Volume
198,157 shs
Average Volume
354,335 shs
Market Capitalization
$336.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Buy

Company Overview

Astria Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

ATXS MarketRank™: 

Astria Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 776th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Astria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Astria Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Astria Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Astria Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Astria Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Astria Therapeutics has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Astria Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.00% of the float of Astria Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Astria Therapeutics has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Astria Therapeutics has recently increased by 1.59%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Astria Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Astria Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.00% of the float of Astria Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Astria Therapeutics has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Astria Therapeutics has recently increased by 1.59%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, Astria Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 4.50% of the stock of Astria Therapeutics is held by insiders.

    • Percentage Held by Institutions

      98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Astria Therapeutics' insider trading history.
    Receive ATXS Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    ATXS Stock News Headlines

    Critical AI announcement set to ignite AI 2.0
    I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
    See More Headlines

    ATXS Stock Analysis - Frequently Asked Questions

    Astria Therapeutics' stock was trading at $8.94 on January 1st, 2025. Since then, ATXS stock has decreased by 33.2% and is now trading at $5.97.

    Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.10.

    Astria Therapeutics shares reverse split before market open on Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

    Astria Therapeutics' top institutional investors include Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Perceptive Advisors Llc and Christopher Morabito.
    View institutional ownership trends
    .

    Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

    Company Calendar

    Last Earnings
    5/13/2025
    Today
    7/19/2025
    Next Earnings (Estimated)
    8/11/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:ATXS
    CIK
    1454789
    Employees
    30
    Year Founded
    2008

    Price Target and Rating

    High Price Target
    $47.00
    Low Price Target
    $16.00
    Potential Upside/Downside
    +402.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.25
    Research Coverage
    8 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($1.87)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$94.26 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -47.18%
    Return on Assets
    -31.26%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    17.39
    Quick Ratio
    17.39

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $3.97 per share
    Price / Book
    1.50

    Miscellaneous

    Outstanding Shares
    56,430,000
    Free Float
    53,894,000
    Market Cap
    $336.89 million
    Optionable
    Optionable
    Beta
    0.41

    Social Links

    Ten Starter Stocks For Beginners to Buy Now Cover

    Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

    Get This Free Report

    This page (NASDAQ:ATXS) was last updated on 7/19/2025 by MarketBeat.com Staff
    From Our Partners